Mark Terndrup’s Post

New pan-cancer scRNA-seq atlas reveals the diverse roles of tumor-infiltrating B cells, uncovering distinct subpopulations and their impact on checkpoint inhibitor therapy responses. A step forward in understanding B cell complexity in the tumor microenvironment, paving the way for new research and therapeutic strategies. https://lnkd.in/dwQuBEgv

📅 22 March is Lynch Syndrome Awareness Day! Lynch Syndrome is a rare condition that increases the risk of developing certain cancers, such as colorectal cancer.   💡 Did you know that 1 in 279 people have Lynch Syndrome, meaning they have a 20-80% lifetime risk of developing colorectal cancer?* 👉 The Idylla™ MSI Test serves as an aid to identify those colorectal cancer patients who should undergo further diagnostic testing for Lynch Syndrome.   Read more here 👀 : https://lnkd.in/emSDiNvz *Win, A.K. et al. (2016) Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 26(3), 404–412. #lynchsyndrome #MSI #Idylla

Black Diamond is developing oral therapeutics for patients with #NSCLC and #GBM. CEO Mark Velleca recently spoke with PharmaVoice about Black Diamond’s vision and clinical programs. Read more in this Biotech Spotlight below, and find us at the American Association for Cancer Research Annual Meeting on April 7 where Etienne Dardenne will be presenting real world data of the evolving #EGFR mutation landscape in #NSCLC, and the first- and best-in-class profile of BDTX-1535. #AACR2024

#Lungcancer #ASCO #HiRO #Taletrectinib Great data Efficacy and Safety of Taletrectinib in Chinese Patients With #ROS1+ #Non–Small Cell Lung Cancer: The Phase II #TRUST-I Study

Labcorp's most recent research, presented at the 2024 SGO Annual Meeting, highlights the crucial role of biomarker testing in guiding personalized treatments for epithelial ovarian cancer. Genomic profiling is transforming patient care, ensuring better patient outcomes through tailored therapies #precisionmedicine #cancerdiagnostics #biotouch https://hubs.li/Q02pYm3c0

The inability of cells to kill themselves is directly linked to both the development of cancer, and resistance to therapy. The major advances in mapping of cell death-associated signalling pathways that led to venetoclax being approved for use in the clinic – and an explosion of associated clinical trial activity – have now firmly established the pharmacological targeting of cell death pathways, including apoptosis and autophagy, as a crucial therapeutic approach in cancer treatment. Our infographic maps the signalling cascades involved in apoptosis and autophagy – highlighting major targets of drug intervention, highly sought-after therapeutic strategies and ongoing clinical trials. Check out the free infographic to learn more: https://okt.to/BFYwWU #Infographic #CellDeath #apoptosis #CancerResearch #ResearchChemicals

"Breaking Ground: OncoHost's NSCLC Test Gains Clinical Validation, Paving the Way for Precision Medicine in Lung Cancer Care. Explore how this innovative approach enhances treatment decisions for Non-Small Cell Lung Cancer patients. #PrecisionMedicine #LungCancer #MedicalInnovation"

A new study highlights the effectiveness of MDX-124, the first therapeutic drug to target annexin-A1, a protein which is overexpressed in several cancer types and promotes tumor progression. https://buff.ly/3unOerm #Research #LifeSciences #Health #Biorealty

Pharmacogenetics in oncology studies enables more targeted patient selection, and data analysis based on genome variations. What could this lead to? Potentially faster, simpler and more cost-effective cancer therapies. Discover more here: https://hubs.li/Q02jY5050 #pharmacogenetics #ClinicalTrials #TrialDesign #OncologyTrials

Check out our new publication: Enfortumab-Vedotin Related Cutaneous Toxicity Correlates with Overall Survival in Patients with Urothelial Cancer https://lnkd.in/gBJvvbk3